Trump’s Fed chair candidates list narrowed down to five by Bessent after interviews, sources say

Key Points

The list of candidates for Fed chair is down to five from 11 after a series of interviews with Treasury Secretary Scott Bessent, according to sources.
The remaining list of candidates includes Fed Vice Chair for Supervision Michelle Bowman, Fed Governor Christopher Waller — along with Kevin Hassett, the director of the National Economic Council.
Former Fed Governor Kevin Warsh and BlackRock Fixed Income CIO Rick Rieder also made the cut.
The individual selected by Trump could be nominated to the Fed — though not necessarily as chair — by January.

Source

Finance

Warren Buffett’s Berkshire Hathaway reveals new position in Alphabet

November 14, 2025

Warren Buffett speaks during the Berkshire Hathaway Annual Shareholders Meeting in Omaha, Nebraska on May 3, 2025. CNBC Warren Buffett’s Berkshire Hathaway revealed a new position in Alphabet, making the Google parent the conglomerate’s 10th largest equity holding at the end of September, according to a regulatory filing. Berkshire disclosed a $4.3 billion stake in […]

Finance

Stocks making the biggest moves midday: Whirlpool, Topgolf Callaway, Nvidia, Stubhub & more

November 14, 2025

Check out the companies making the biggest moves midday: Scholar Rock — The Cambridge, Massachusetts-based biotech jumped 23% after saying it ” completed constructive and collaborative in-person Type A meeting ” with the FDA on Wednesday for a biologics license application for apitegromab, a spinal muscular atrophy treatment. Officials from Novo Nordisk’s Catalent Indiana joined […]

Finance

Stocks making the biggest premarket moves: Warner Bros. Discovery, Cidara Therapeutics, Avadel Pharmaceuticals and more

November 14, 2025

Check out the companies making headlines before the bell. Cidara Therapeutics — Shares of Cidara surged 103% after Merck agreed to buy the company for close to $9.2 billion in cash. Merck fell 1%. Avadel Pharmaceuticals — Danish drugmaker Lundbeck offered to acquire the pharmaceutical company for as much as $23 per share, topping biotech […]